Wholomics, founded by researchers from Dana Farber and University College London, presented new data demonstrating its serum-based metabolomic platform’s ability to detect multiple cancers at early stages, including colorectal, lung, pancreatic, and other tumors. Utilizing nuclear magnetic resonance technology, the approach identifies metabolic, lipidomic, and lipoproteomic cancer signatures distinct from DNA-based liquid biopsy tests. Early results were shared at the American Society for Clinical Oncology, highlighting sensitivity improvements especially in pancreatic cancer, a tumor type with a critical unmet diagnostic need.